Renub Research has recently published a report titled “North America Kidney Transplant Market: North America Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” providing a comprehensive analysis of the industry that includes market share insights. In addition, the report comprises competitor and regional research and contemporary extension. North America Kidney Transplant Market is projected to grow with a CAGR of 5.38% over the forecast period (2023-2027).
The North America kidney transplant industry is a dynamic and rapidly evolving sector within the healthcare landscape. With advancements in medical technology, surgical techniques, and immunosuppressive therapies, kidney transplantation has become an established and successful treatment option for end-stage renal disease (ESRD) patients. North America, comprising the United States and Canada, has emerged as a prominent region in the field of kidney transplantation, with a robust infrastructure, well-equipped transplant centers, and a large pool of skilled healthcare professionals. The region also benefits from extensive research and development activities, fostering innovation and improving patient outcomes. North America Kidney Transplant Market is projected to reach a value of US$ 14.76 Billion by 2027 due to growing demand for kidney transplantation | Renub Research
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=kidney-transplant-market-numbers-and-forecast-for-united-states-mexico-and-canada-302-p.php
Additionally, favorable reimbursement policies, government initiatives, and increased awareness about organ donation have contributed to the growth of the North America kidney transplant industry. As a result, the industry is expected to witness continued growth and advancements in the coming years, providing renewed hope and improved quality of life for ESRD patients.
In 2022, the United States kidney transplant industry achieved a remarkable milestone with over 25,000 life-saving kidney transplants performed, setting a new record in the region. However, the demand for kidney transplantation continues to outpace the supply of available organs. As of May 2023, the United States alone has 88,753 individuals on the waiting list for a kidney transplant, according to the United Network for Organ Sharing (UNOS). This staggering number highlights the urgent need for increasing organ donations and improving transplant processes. Efforts are underway to raise awareness about organ donation, enhance organ procurement and allocation systems, and promote research and development in the field of kidney transplantation. By addressing these challenges and expanding access to transplantation, the North America kidney transplant industry aims to save more lives and improve the quality of life for patients suffering from end-stage renal disease.
United States has positioned itself as the frontrunner in the kidney transplant industry, leading the market with the highest market share
Renowned for its well-developed healthcare system, advanced medical facilities, and robust infrastructure, the country has become a preferred destination for individuals seeking kidney transplantation. With top-tier transplant centres and highly skilled healthcare professionals specializing in successful kidney transplant procedures, the United States offers exceptional expertise in the field.
Moreover, the country’s continuous progress in immunosuppressive therapies, surgical techniques, and organ procurement processes has further solidified its dominant market position. The substantial market share of the United States in the kidney transplant industry demonstrates its unwavering commitment to delivering quality healthcare services and driving improved outcomes for patients with end-stage renal disease.
Region – Kidney Transplant Market breakup from 3 Regions:
1. United States
2. Canada
3. Mexico
Living Donor Transplant market is on track to witness significant growth in the foreseeable future
Living donor transplantation offers numerous advantages, including superior outcomes, reduced waiting times, and improved graft survival rates when compared to deceased donor transplantation. These compelling benefits, coupled with the increasing awareness and acceptance of living donor transplantation, are serving as key drivers for market expansion. Furthermore, continuous advancements in surgical techniques, immunosuppressive therapies, and organ preservation methods have substantially enhanced the success rates of living donor transplants, further augmenting the market’s growth trajectory. The rising demand for organs, coupled with the persistent shortage of deceased donor organs, has underscored the importance of living donor transplantation as a viable solution. Consequently, the Living Donor Transplant market is projected to experience remarkable growth in the coming years, bringing immense benefits to patients in the need of organ transplantation and contributing to the advancement of the broader healthcare industry.
Type – Kidney Transplant Market breakup from 2 viewpoints:
1. Deceased Donor Transplant
2. Living Donor Transplant
Calcineurin inhibitors are a vital class of immunosuppressive drugs widely employed in North America kidney transplant market
The Calcineurin Inhibitors market is experiencing significant growth driven by advancements in technology and healthcare. These inhibitors play a crucial role in immunosuppressive therapy for organ transplantation and autoimmune disorders. Research and development efforts have led to improved formulation, delivery, and effectiveness of these inhibitors. Innovations in drug delivery systems and bioavailability have increased demand. Factors such as the rising rates of organ transplantation, incidence of autoimmune diseases, and aging population contribute to market growth. The integration of digital healthcare solutions like telemedicine and remote monitoring has further accelerated the adoption of calcineurin inhibitors.
Drugs – Kidney Transplant Market breakup from 4 viewpoints
1. Calcineurin inhibitors
2. Antiproliferative agents
3. mTor inhibitor
4. Steroids
5. Antibodies
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Contact Us:
Renub Research
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Email: [email protected]
LinkedIn: https://in.linkedin.com/company/renub-research
Web: www.renub.com
About The Author
